Q&A: PhRMA CEO Stephen Ubl on the IRA, challenges to the FDA’s authority and the US-China relationship

Nicole DeFeudis

Editor

As we approach the 2024 presidential election, Stephen Ubl, president and CEO of the pharmaceutical industry’s DC-based trade group PhRMA, said “the political process has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Q&A: PhRMA CEO Stephen Ubl on the IRA, challenges to the FDA’s authority and the US-China relationship

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Edgewise’s stock surges as heart drug passes early safety test

Stem cell startup spun out of George Church’s lab raises $75M

Breaking down silos with a new quantitative approach to drug development

Q&A: PhRMA CEO Stephen Ubl on the IRA, chal­lenges to the FDA’s au­thor­i­ty and the US-Chi­na re­la­tion­ship

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Q&A: PhRMA CEO Stephen Ubl on the IRA, challenges to the FDA’s authority and the US-China relationship